6533b837fe1ef96bd12a3175

RESEARCH PRODUCT

The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis

Daphne MytilineosDaphne MytilineosDaphne MytilineosChrysanthi TsamadouChrysanthi TsamadouChristine NeuchelChristine NeuchelUwe PlatzbeckerDonald BunjesNatalie SchubEva Wagner-drouetGerald WulfNicolaus KrögerNiels MurawskiHermann EinseleKerstin Schaefer-eckartSebastian FreitagJochen CasperMartin KaufmannMareike DürholtBernd HertensteinStefan KleinMark RinghofferCarlheinz R. MuellerCarlheinz R. MuellerSandra FrankHubert SchrezenmeierHubert SchrezenmeierDaniel FuerstDaniel FuerstJoannis MytilineosJoannis MytilineosJoannis Mytilineos

subject

MalePermissivenessOncologyGraft vs host diseaseEpitopes T-LymphocyteGraft vs Host DiseaseKaplan-Meier Estimategraft-versus-host-disease0302 clinical medicineGermanyImmunology and AllergyChild3' Untranslated RegionsHLA-DP beta-ChainsBone Marrow TransplantationOriginal Research0303 health sciencesHistocompatibility TestingIncidenceStem cell transplantationMiddle AgedAllograftsAllotype3. Good healthHLA-DPB1Child PreschoolHistocompatibility030220 oncology & carcinogenesisFemaleUnrelated Donorslcsh:Immunologic diseases. AllergyAdultRiskmedicine.medical_specialtyAdolescentImmunologyGraft vs Leukemia EffectHuman leukocyte antigenPolymorphism Single Nucleotidestem cell transplantationRelapse free survivalLymphocyte DepletionYoung Adult03 medical and health sciencesInternal medicinemedicineHumansTransplantat-Wirt-Reaktionddc:610PermissivePeriphere StammzellentransplantationAllelesAgedRetrospective Studies030304 developmental biologyPeripheral Blood Stem Cell TransplantationHLA-DPB1Donor selectionbusiness.industryInfant NewbornModels ImmunologicalInfantmedicine.diseaseGraft-versus-host diseaseHLA-DPB1-permissivenessHLA-DPB1 expressionlcsh:RC581-607business

description

T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events in large international cohorts. We retrospectively genotyped HLA-DPB1 in 3523 patients transplanted in Germany between 2000 and 2014 and in their unrelated donors using an Illumina amplicon-NGS based assay. Aim of the study was to evaluate DP-compatibility beyond the established TCE3 algorithm by assessing the combined effect of several DP-mismatch parameters on post-transplant outcome. We implemented an extended DP-mismatch assessment model where TCE3, DP allotype expression with respect to rs9277534, mismatch vector and number of mismatches were conjointly taken into consideration. In this model, non-permissive HLA-DPB1 mismatches showed significantly increased aGvHD risk if they were accompanied by two HLA-DPB1 mismatches in GvH direction (HR: 1.46) or one mismatched highly expressed patient allotype (HR: 1.53). As previously reported, non-permissive HLA-DPB1 mismatches associated with a significantly higher risk of aGvHD and non-relapse mortality (HR 1.36 and 1.21, respectively), which in turn translated into worse GvHD and relapse free survival (HR 1.13). Effects on GvL and GvHD appeared strongest in GvH-directed non-permissive mismatches. Our study results support the consideration of additional HLA-DPB1 mismatch parameters along with the established TCE3 matching algorithm for refinement of future donor selection. In particular, our findings suggest that DP non-permissiveness associated with two HLA-DPB1 mismatches or at least on highly expressed mismatched patient allotype should be avoided.

https://doi.org/10.3389/fimmu.2020.614976